Tevogen highlights need for SARS-CoV-2 treatments for immunocompromised

WARREN, N.J. - Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a clinical-stage biotech company with a market capitalization of $175 million, emphasized the ongoing need for SARS-CoV-2 treatments for immunocompromised individuals who face higher risks from the virus, according to a press release issued Wednesday. Despite showing strong momentum with an 89% return over the past year, InvestingPro analysis indicates the stock is currently overvalued based on its proprietary Fair Value model.

The company’s investigational treatment, TVGN 489, is an allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte immunotherapy developed using its ExacTcell platform. The therapy targets the entire viral genome rather than a single protein. While analysts maintain a Strong Buy rating with a $10 price target, InvestingPro data reveals the company faces financial challenges with negative EBITDA of $31 million in the last twelve months.

In a clinical trial, high-risk patients, including immunocompromised individuals, received a single infusion of TVGN 489. The company reported that treated patients showed faster symptom resolution compared to the standard care group. Viral elimination reached over 99% in all treated patients by day 14, with no disease progression or Long COVID observed in this group. According to InvestingPro, which offers 7 additional key insights about TVGN’s financial health and market position, the company operates with a moderate level of debt while maintaining development efforts.

The treatment was well-tolerated at all four dose levels tested and did not impair patients’ existing immune responses. The company noted that the cytotoxic T lymphocytes persisted in treated patients through six months of follow-up.

"An intact immune system is necessary to cure viral infections and TVGN 489 is designed to directly provide this immune help to individuals who need it," said Dr. Ryan Saadi, CEO of Tevogen Bio, in the statement.

Dr. Neal Flomenberg, Chief Science Officer at Tevogen, added that the current XFG variant surge demonstrates that "COVID-19 is not limited to just the winter months and remains a threat to those with weakened immune systems."

The company stated that TVGN 489’s targets remain unaffected by mutations, including the current XFG SARS-CoV-2 variant.

In other recent news, Tevogen Bio Holdings Inc. reported a significant 60% increase in institutional ownership of its common stock during the first quarter of 2025, with Vanguard and BlackRock being major contributors to this growth. The company also announced it expects to receive $1 million in grant funding from KRHP LLC to further its Tevogen.AI drug discovery platform, as part of a larger $10 million non-dilutive funding agreement. Additionally, Tevogen disclosed that its executives and directors own over 74% of the company’s stock, positioning the leadership team to maintain control over strategic decisions.

Tevogen’s Board of Directors recently granted 8 million restricted shares to CEO Dr. Ryan Saadi, updating the total number of outstanding shares to 193,693,433. The company has also entered into a $50 million at-the-market equity offering agreement with A.G.P./Alliance Global Partners, allowing for the sale of common stock as needed. These developments highlight Tevogen Bio’s ongoing efforts to secure funding and strengthen its leadership’s influence over the company’s direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.